Liposomal Doxorubicin Market Report 2026

Liposomal Doxorubicin Market Overview

• Liposomal Doxorubicin market size has reached to $1.32 billion in 2025 • Expected to grow to $1.77 billion in 2030 at a compound annual growth rate (CAGR) of 5.9% • Growth Driver: Rising Prevalence Of Cancer Fuels Growth In Liposomal Doxorubicin Market • Market Trend: Emerging Trends In Cost-Effective Liposomal Chemotherapy • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Liposomal Doxorubicin Market?

Liposomal doxorubicin refers to a formulation of the chemotherapy drug doxorubicin encapsulated within lipid bilayers, creating microscopic vesicles called liposomes. This encapsulation alters its pharmacokinetics, allowing for prolonged circulation in the bloodstream and accumulation at tumor sites due to enhanced permeability and retention effects. Liposomal doxorubicin is used to treat various cancers, including ovarian cancer, breast cancer, and Kaposi's sarcoma, with potentially reduced cardiotoxicity compared to conventional doxorubicin formulations. The main product types of liposomal doxorubicin are Doxil or Caelyx, Lipodox, Myocet, and others. Doxil, also known as Caelyx, is a brand name for liposomal doxorubicin, a chemotherapy drug used to treat various types of cancer. The routes of administration include parenteral and others, and its applications are leukemia, bone sarcoma, breast cancer, endometrial cancer, kidney cancer, multiple myeloma, Kaposi sarcoma, and others. It is used by various end-users, such as hospitals, home care, and others.

What Is The Liposomal Doxorubicin Market Growth Forecast?

The liposomal doxorubicin market size is expected to see strong growth in the next few years. It will grow to $1.77 billion in 2030 at a compound annual growth rate (CAGR) of 5.9%. The growth in the forecast period can be attributed to rising demand for safer cancer therapies, increasing focus on patient quality of life, expansion of oncology treatment access in emerging markets, growth in liposomal drug development pipelines, increasing approvals of generic oncology drugs. Major trends in the forecast period include growing preference for targeted chemotherapy formulations, increasing use of liposomal drugs to reduce cardiotoxicity, rising adoption in ovarian and breast cancer treatment, expansion of generic liposomal doxorubicin products, growing demand for improved drug tolerability in oncology.

What Is The Driver Of The Liposomal Doxorubicin Market?

The rising prevalence of cancer is expected to propel the growth of the liposomal doxorubicin market going forward. Cancer refers to a category of illnesses that can develop in nearly any organ or tissue in the body when aberrant cells proliferate uncontrollably, cross their normal boundaries, and either spread to other organs or invade neighboring body parts. Cancer cases are rising due to factors such as an aging population, lifestyle changes, environmental exposures, and improved diagnostic techniques. Liposomal doxorubicin is used in cancer treatment to enhance drug delivery to tumors, reduce toxicity, and improve therapeutic outcomes. For instance, in January 2024, according to the American Cancer Society, a US-based nonprofit cancer advocacy organization, the number of cancer cases increased to 2,001,140 compared to 1,958,310 in 2023, reflecting a growth of 2.19%. Therefore, the rising prevalence of cancer is driving the growth of the liposomal doxorubicin industry.

Key Players In The Global Liposomal Doxorubicin Market

Major companies operating in the liposomal doxorubicin market are Johnson & Johnson, Pfizer Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Cipla Ltd., Lupin Limited, Zydus Lifesciences Ltd., Accord Healthcare Limited, Dr. Reddy’s Laboratories Ltd., Hikma Pharmaceuticals PLC, Intas Pharmaceuticals Ltd., Mylan N.V., Apotex Inc., Natco Pharma Limited, Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co. Ltd., TTY Biopharm Company Limited, CSPC Pharmaceutical Group Limited, Luye Pharma Group Ltd., Qilu Pharmaceutical Co. Ltd., Chia Tai Tianqing Pharmaceutical Group, SRS Life Sciences

Global Liposomal Doxorubicin Market Trends and Insights

Major companies operating in the liposomal doxorubicin market are focusing on developing innovative liposomal injectable formulations, such as ready-to-use liposomal doxorubicin presentations, to improve therapeutic index, reduce systemic toxicity, and simplify hospital administration compared with conventional free-drug doxorubicin infusions. Liposomal doxorubicin is a nanoparticle-encapsulated formulation in which doxorubicin is sequestered within lipid bilayer vesicles (liposomes) that alter pharmacokinetics and biodistribution, key features include prolonged circulation time, preferential tumor accumulation via the enhanced permeability and retention (EPR) effect, reduced cardiotoxicity and altered tissue exposure versus non-encapsulated doxorubicin, and compatibility with combination regimens. For instance, in July 2024, ForDoz Pharma Corp., a US–based specialty pharmaceutical company, received FDA approval for DOXOrubicin Hydrochloride Liposome Injection in ready-to-use 20 mg/10 mL and 50 mg/25 mL presentations for ovarian cancer, AIDS-related Kaposi’s sarcoma, and multiple myeloma (with bortezomib), with the liposomal formulation enabling sustained, tumor-targeted drug delivery and reduced peak-related toxicity, while its prefilled, standardized vials simplify preparation and dosing, offering improved tolerability, suitability for combination therapy, and enhanced treatment workflow across solid tumor and hematologic oncology settings.

What Are Latest Mergers And Acquisitions In The Liposomal Doxorubicin Market?

In January 2024, CHEPLAPHARM Arzneimittel GmbH, a Germany-based pharmaceutical company, acquired European rights to Myocet from Teva Pharmaceutical Industries Ltd. for an undisclosed amount. This acquisition enhances CHEPLAPHARM's oncology portfolio with the addition of Myocet, a non-pegylated liposomal doxorubicin formulation, aligning with its strategy to integrate well-established drugs. Teva Pharmaceutical Industries Ltd. is an Israel-based pharmaceutical company offering liposomal doxorubicin formulation Myocet.

What Defines the Liposomal Doxorubicin Market?

The liposomal doxorubicin market consists of sales of Doxil and Lipodox. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Liposomal Doxorubicin Market Report 2026?

The liposomal doxorubicin market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the liposomal doxorubicin industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.